Stocktoria
RECURSION PHARMACEUTICALS, INC. RXRX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-04-16
RECURSION PHARMACEUTICALS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $74.7M | $58.8M | $44.6M | $39.8M | $10.2M |
| R&D expense | $475.3M | $314.4M | $241.2M | $155.7M | $135.3M |
| Operating income | -$648.1M | -$479.0M | -$350.1M | -$245.7M | -$182.8M |
| Interest expense | — | — | $97,000 | $55,000 | $3.0M |
| Income tax | -$136,000 | -$1.1M | -$4.1M | $0 | $0 |
| Net income | -$644.8M | -$463.7M | -$328.1M | -$239.5M | -$186.5M |
| EPS (diluted) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 |
| Operating cash flow | -$371.8M | -$359.2M | -$287.8M | -$83.5M | -$158.6M |
| Free cash flow | -$378.3M | -$372.9M | -$299.7M | -$120.6M | -$198.4M |
| Cash & equivalents | $743.3M | $594.4M | $391.6M | $549.9M | $285.1M |
| Total assets | $1.5B | $1.4B | $653.7M | $701.3M | $610.3M |
| Total liabilities | $343.3M | $413.8M | $190.3M | $215.5M | $67.4M |
| Shareholders' equity | $1.1B | $1.0B | $463.4M | $485.8M | $542.9M |
Source: SEC EDGAR filings · CIK 0001601830 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.